Category: Fellows Posters
Prescription drug advertising and promotion is highly regulated around the world. Recently, prescription drug advertising and promotion has pivoted to a scrutinized and prioritized topic in both the United States (US) and the rest of the world. This poster will compare prescription drug advertising and promotion regulations in select countries around the world to evaluate the impact they may have on consumers and healthcare providers.
Information was gathered regarding regulatory and legal requirements for advertising and promotion from governing agency webpages and the International Comparative Legal Guide for countries around the world. In addition, we utilized current news articles and journal publications to further compare country specific regulations. Five countries were selected to compare advertising requirements and evaluate the impact advertising and promotional requirements may have on companies, health care providers (HCPs), and consumers.
Country specific regulations revealed information regarding similarities and differences amongst each country. The countries selected for evaluation were the United States (US), New Zealand, Sweden, France, and Japan. Categories compared included direct-to-consumer-advertising (DTC), HCP endorsements, comparative advertisement requirements, press releases, and distribution of scientific papers. The differences in regulations varied based on audience, content, and platform. Laws, regulations, and case law continue to change in order to define how regulatory agencies interpret promotional materials from pharmaceutical companies. While each country has different requirements, the underlying theme of providing a non-misleading message to patients and HCPs was consistent.
Understanding variations in prescription drug advertising and promotion regulations around the world helps us understand global use trends and why they may vary between countries. Healthcare providers consumption of prescription drug advertising and promotion impacts patient care decisions. Advertising and promotion directly impacts HCP interpretation and application of clinical data leading to expert opinion and treatment guidelines. Many countries have regulatory documents and guidance, yet there is still ambiguity in interpretation and application. Understanding regulations globally can assist companies and organizations to comply with regulatory standards whilst guiding providers to make appropriate therapy and care decisions.